Navigation Links
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
Date:5/7/2008

eak and trough concentrations as seen with immediate-release guanfacine. INTUNIV is not a controlled substance and does not appear to have a known mechanism for potential abuse or dependence.

Although other ADHD medications work indirectly in the prefrontal cortex, it has been shown that guanfacine, the active ingredient in INTUNIV, works directly by binding selectively to alpha-2A adrenergic cell receptors located in the prefrontal cortex. The prefrontal cortex is an area of the brain associated with executive functioning, ie, working memory, behavioral inhibition, regulation of attention, distractibility, impulsivity, and frustration tolerance. The selective alpha-2A agonist strengthens working memory and prefrontal cortex neuronal firing. This research supports the use of guanfacine for the treatment of ADHD.

Safety data showed that adverse events reported by participants using INTUNIV were generally mild to moderate in severity, with the most common side effects being sedative in nature. Sedation-related, treatment-emergent adverse events were among the most common but emerged in the first two weeks and were usually transient and mild or moderate in severity. Treatment-related adverse events greater than 10 percent included somnolence (32 percent), headache (26 percent), fatigue (18 percent), upper abdominal pain (14 percent) and sedation (13 percent). Small to modest changes in blood pressure, pulse rate, and ECG parameters were observed.

About ADHD

ADHD is one of the most common psychiatric disorders in children and adolescents. Approximately 7.8 percent of all school-aged children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). The disorder is also estimated to affect 4.4 percent of U.S. adults aged 18-44 based on results from the National Comorbidity Survey Replication, a nationally representa
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
3. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
4. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
5. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
6. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
7. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
8. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
9. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Amgen ... the submission of a Marketing Authorization Application ... via the centralized procedure for talimogene laherparepvec ... with melanoma that is regionally or distantly ... administered as an intralesional injection that is ...
(Date:9/2/2014)... FRANCISCO, Calif. , Sept. 2, 2014   Veracyte, ... Bonnie H. Anderson , president and chief executive officer, ... Morgan Stanley Global Healthcare Unplugged Conference 2014 on Monday, September ... York . The live audio webcast and ... http://investor.veracyte.com . Please connect to the website at least ...
(Date:9/2/2014)... Redspin, Inc., a leading provider of HIPAA ... an IT security advisory specifically for senior executives in ... presiding over the most dynamic period in the history ... Redspin,s President and CEO. "The goal of our advisory ... understand why they need to elevate IT security to ...
Breaking Medicine Technology:Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... importance of dedicated information management systems for radiation ... most recent version of its MOSAIQ® Oncology Information ... Systems Society,s 2012 conference (HIMSS12), Feb. 20-24, in ... comprehensive OIS that centralizes traditional radiation oncology, particle ...
... Feb. 16, 2012  Cardium Therapeutics (NYSE Amex: ... previously announced sale of 17,857,143 shares of its common ... of approximately $5.0 million, before deducting placement agent,s fees ... investors participating in the offering purchased the shares at ...
Cached Medicine Technology:Elekta Highlights Latest Version of MOSAIQ Oncology Information System at HIMSS12 Meeting 2Cardium Announces Closing of $5.0 Million Equity Financing 2Cardium Announces Closing of $5.0 Million Equity Financing 3
(Date:9/2/2014)... Humility of Mary Health Partners will offer a ... Health Center, 1044 Belmont Ave. , The workshop includes an ... common health problems as well as tips on caring for ... on when to seek medical attention. , The morning ... Room; the evening session runs from 5:30 to 6:30 p.m. ...
(Date:9/2/2014)... 02, 2014 A little bit of ... sometimes the onset of irritability, sadness, or apathy can ... September 2014 Harvard Health Letter. , "Mood-related ... stresses. If they occur for long periods, cause significant ... to seek help," says Dr. Nancy Donovan, an instructor ...
(Date:9/2/2014)... Eric Jimenez and Leah Ashley announced ... revolutionary makeup application device. Designed to improve and accelerate ... the palm of women’s hands to help them get ... Me’s success lies in its patented technology. With a ... 15,000 pulses per minute, the device applies foundation evenly ...
(Date:9/2/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief executive officer ... Sioux Falls, S.D. The top executive search firm in ... more than 900 healthcare executives into organizations. , ... and nationally recognized leader in patient-centered care. It is ...
(Date:9/2/2014)... Syracuse, NY (PRWEB) September 02, 2014 ... A. Gadlage, M.D. & Associates in Duluth, GA and ... the EarQ team at the 2014 National ... in Cancun, Mexico. , While interacting with the former ... maintaining hearing health, the team provided free hearing screenings, ...
Breaking Medicine News(10 mins):Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:When a Mood Swing Signals Trouble, From the September 2014 Harvard Health Letter 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 3Health News:The EarQ Team Brings Hearing Health Awareness to the 2014 National Basketball Retired Players Association Annual Convention in Cancun 2
... a few glasses of wine enough to disrupt normal development, ... Just a few glasses of wine over a short period ... the Medical College of Georgia. , The initial signs ... include facial malformations such as a flat and high upper ...
... Benefit Muscular Dystrophy Research , ... Iselin, NJ (PRWEB) ... [Sanford-Brown Iselin] (SBI), in New Jersey, raised $11,000 for muscular ... the event are in support of local non-profit www.ryansquest.org ...
... to recent news,about Michigan,s first identified case of chronic ... issued the following statement., With hunting season fast ... a deer on a Kent County farm understandably has,created ... great state of Michigan. The deer farming industry in ...
... Surgery Seems to be the Provider of Choice for Recent,Big ... Next?, Months of constant cameras, mirrors all around and ... a major impact on how you feel,about the way you ... reality. Upon leaving the house contestants may undoubtedly spend,hours watching ...
... to $19 million, NATICK, Mass., Aug. 29 ... the U.S. District Court of,Marshall, Texas found two patents ... conduct during the prosecution of the patents,before the United ... previously found that certain Boston Scientific balloon,catheters and stent ...
... leadership and State delegations as a possible solution to national health ... ... 2008 -- If there has been any one consistent message offered ... the party platform initiative to resolve our national health care issues., ...
Cached Medicine News:Health News:Alcohol in Early Pregnancy May Prompt Fetal Cell Death 2Health News:Sanford-Brown Institute - Iselin Raises $11,000 for Ryan's Quest 2Health News:Deer Farm Industry in Michigan Issues Statement on the Recent Chronic Wasting Disease Case Identified on a Kent County Deer Farm 2Health News:MYA Makes Big Brother Stars Amazing! 2Health News:MYA Makes Big Brother Stars Amazing! 3Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3Health News:AMD Global Telemedicine Inc. Invited to Attend Democratic National Convention 2
...
The Tew cranial/spinal retractor is designed for posterior fossa or intraspinal microsurgery where retraction is required. Clinical applications are: Posterior fossa microsurgery and intraspinal micr...
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required....
Medicine Products: